Karen A Autio - JoVE Visualize

Showing results (31-40 of 42) with videos related to

Pageof 5

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.

Journal for Immunotherapy of Cancer|March 22, 2023

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)Karen A Autio, Celestia S Higano, Luke Nordquist, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2024

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate CancerAndrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.

Cancer Research Communications|December 18, 2023

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United StatesEmily M Rencsok, Natalie Slopen, Hannah D McManus, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.

European Urology Open Science|December 22, 2021

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.

JAMA Oncology|December 28, 2018

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint BlockadeWassim Abida, Michael L Cheng, Joshua Armenia, et al.

Journal for Immunotherapy of Cancer|March 17, 2023

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025

Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical TrialDeaglan McHugh, Matthew Dallos, Min Yuen Teo, et al.

Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:

Pageof 5

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.

Journal for Immunotherapy of Cancer|March 22, 2023

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)Karen A Autio, Celestia S Higano, Luke Nordquist, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2024

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate CancerAndrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.

Cancer Research Communications|December 18, 2023

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United StatesEmily M Rencsok, Natalie Slopen, Hannah D McManus, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.

European Urology Open Science|December 22, 2021

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.

JAMA Oncology|December 28, 2018

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint BlockadeWassim Abida, Michael L Cheng, Joshua Armenia, et al.

Journal for Immunotherapy of Cancer|March 17, 2023

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025

Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical TrialDeaglan McHugh, Matthew Dallos, Min Yuen Teo, et al.

Pageof 5